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Abstract
We evaluated the prevalence of the metabolic syndrome (MS) and of 
hyperhomocysteinemia in patients with unprovoked deep vein thrombosis (DVT) and in 
controls. The MS and hyperhomocysteinemia were significantly more prevalent in DVT 
patients than in controls. However, only the MS resulted independently associated with 
DVT, and the coexistence of both risk factors did not increase the magnitude of the 
association.
metabolic syndrome hyperhomocysteinemia deep vein thrombosis
High plasma homocysteine levels are common in patients who have suffered venous 
thromboembolic event (VTE), and several case-control studies and recent meta-analyses 
have shown higher plasma homocysteine levels in patients with VTE compared to 
controls.1
The metabolic syndrome (MS), a group of cardiovascular risk factors, is associated with a 
3 to 4 fold increase in the incidence of cardiovascular disease.2,3
Hyperhomocysteinemia seems to be an additional risk factor for cardiovascular disease 
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in patients affected by the MS.4,5 We recently found that patients with unprovoked deep 
vein thrombosis (DVT) had a significantly higher prevalence of the MS than control 
subjects without thrombosis suggesting the MS has a role in the pathogenesis of DVT.6
However, there have been no studies to assess the relationship between 
hyperhomocysteinemia and the MS in the pathogenesis of DVT.
This study evaluates part of the population included in our previous study6 to determine 
whether the presence of the MS is associated with elevated levels of homocysteine in 
patients with DVT, and to assess the relationship between the MS and plasma 
homocysteine levels in these patients. In a case-control study, consecutive patients with 
objectively confirmed, unprovoked DVT and control subjects with objectively excluded 
DVT underwent clinical assessment for the presence of the MS according to the National 
Cholesterol Education Program criteria.7 Fasting plasma levels of total homocysteine 
were measured in patients and in controls. Hyperhomocysteinemia was defined by 
homocysteine levels above 15 μmol/L. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were used as a measure of association between DVT and hyperhomocysteinemia 
and between DVT and the presence of the MS. Interaction between 
hyperhomocysteinemia and the MS on the development of DVT was evaluated using a 
logistic regression model. Eighty four patients with unprovoked DVT and 94 controls 
were enrolled.
Patients’ baseline characteristics are summarized in Table 1. Hyperhomocysteinemia 
was significantly more common in patients with unprovoked DVT than in controls (32/84 
vs 27/94; OR 1.95; 95% CI 1.00–3.81). There was no significant difference in mean 
homocysteine levels between patients with unprovoked DVT and in controls (18.7 vs 
15.0 μM; p=0.08). Adjustment for possible confounding factors (age, gender, smoking 
habits) did not affect results.
Table 1.
Baseline characteristics.
Hyperhomocysteinemia was significantly more common in patients with the MS than in 
patients without (35/75 vs 29/103; OR 2.23; 95% CI 1.14–4.28). After multivariate 
analysis, the presence of hyperhomocysteinemia remained independently associated with 
the presence of the MS.
Twenty two patients with unprovoked DVT (26.2%) and 12 controls (12.8%) had both 
hyperhomocysteinemia and the MS. This association was significantly more prevalent in 
patients with unprovoked DVT than in controls (OR 2.42; 95% CI 1.05–5.67).
The MS was significantly more common in patients with idiopathic DVT than in controls 
(43/84 vs 32/94; OR 2.03; 95% CI 1.06–3.89). Multivariate analysis was performed to 
assess factors associated with unprovoked DVT and controls. This analysis found male 
gender (OR 2.64; 95% CI 1.40, 4.98) and the MS (OR 2.14; 95% CI 1.12, 4.08) to be 
independently associated with unprovoked DVT, whereas the presence of 
hyperhomocysteinemia was not seen to be independently associated with the presence 
of unprovoked DVT.
In conclusion, we found that hyperhomocysteinemia was significantly more common in 
patients with the MS than in patients without. This association remained significant after 
controlling for potential confounders. Although both the MS and hayperhomocysteinemia 
were significantly more prevalent in DVT patients than in controls, only the MS resulted 
to be independently associated with DVT, and the coexistence of both risk factors did not 
increase the magnitude of the association.
A number of studies and meta-analyses1,8,9 have reported an association between 
hyperhomocysteinemia and DVT. The mechanisms by which hyperhomocysteinemia 
might induce DVT have not been completely clarified, but may include effects on the 
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endothelium and on the coagulation cascade.10 Given the high prevalence of 
hyperhomocysteinemia in patients with the MS, and the recently reported association 
between this latter and unprovoked DVT, there was a rationale to suggest that 
hyperhomocysteinemia might have been the cause of such association. However, the 
results of our study suggest that the potential role of the MS in the pathogenesis of 
unprovoked DVT is not mediated by the presence of hyperhomocysteinemia. On the 
contrary, when adjusted for the presence of the MS, hyperhomocysteinemia was not 
seen to be an independent risk factor for DVT, and its increased prevalence in patients 
with unprovoked DVT may be explained, at least in part, by the presence of the MS. 
Therefore, it is possible that hyperhomocysteinemia is an epiphenomenon rather than a 
risk factor. However, these preliminary results need to be confirmed in larger 
prospective studies.
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